Monofocal vs Multifocal IOLs: A Surgeon's Decision Framework

Monofocal vs Multifocal IOLs: A Surgeon's Decision Framework

You have twelve minutes between cases, and the patient in chair three is asking whether she should "just pay extra for the lens that fixes everything." Behind her waits a retired pilot with 20/20 expectations and a driver with early macular change. The monofocal-versus-multifocal question is not a product question — it is a triage question, a counselling question, and, increasingly, a practice-economics question. This framework condenses the published evidence and the hard-won lessons of premium-channel surgery into a repeatable decision process you can run at the slit lamp.

What the Evidence Actually Says

Before patient preference enters the room, it helps to anchor the discussion in what controlled data support.

The Cochrane systematic review by de Silva and colleagues (Cochrane Database of Systematic Reviews, 2016) compared multifocal and monofocal IOLs after cataract extraction and found that multifocal lenses improved near vision and reduced spectacle dependence, while distance visual acuity was broadly comparable between the two designs. The trade-off was consistent: multifocal recipients reported more unwanted visual phenomena — halos and glare in particular.

A comprehensive literature review by de Vries and Nuijts (Journal of Cataract & Refractive Surgery, 2013) reached a similar conclusion: multifocal IOLs deliver on spectacle independence for appropriately selected patients, but contrast sensitivity is modestly reduced and dysphotopsia complaints cluster in the early postoperative months before neuroadaptation.

More recent work on trifocal designs, such as the randomised comparisons reviewed by Kohnen and colleagues (Ophthalmology, 2015 onward), shows that diffractive trifocal optics add a useful intermediate focal point, narrowing the gap for screen-distance tasks — but the fundamental physics of light-splitting optics has not changed. Every photon allocated to a near focus is a photon subtracted from distance contrast.

Three clinical facts follow:

• Spectacle independence is real but not universal. Across studies, roughly 70–90% of well-selected multifocal patients report being glasses-free for most activities; monofocal patients typically retain readers.
• Dysphotopsia is the tax. Halo and glare are the price of the diffractive optic. Most patients adapt within three to six months; a small minority do not.
• Contrast and comorbidity tolerance are lower. Any condition that steals contrast — maculopathy, glaucoma, significant corneal irregularity, amblyopia — disproportionately penalises a light-splitting lens.

The Four-Question Framework

We recommend structuring the decision around four sequential questions. A "no" at any gate routes the patient toward a monofocal (or enhanced monofocal / EDOF) pathway.

1. Is the eye optically healthy enough to share light?

This is the hardest gate and the one most often skipped under time pressure. Before offering a multifocal, confirm:

• Macula: OCT screening for epiretinal membrane, drusen, diabetic maculopathy. Even mild ERM degrades multifocal performance disproportionately.
• Cornea: Regular astigmatism within the lens's correction range, no significant irregular astigmatism, dry-eye disease treated and stabilised before biometry.
• Optic nerve and visual field: Glaucoma beyond ocular hypertension is generally a multifocal contraindication; split-light optics sacrifice contrast the nerve cannot spare.
• Pupil and angle: No significant pupil abnormalities that would decouple the diffractive rings from the visual axis.

If any gate fails, a high-quality monofocal IOL — particularly an aspheric, aberration-correcting design — protects contrast and delivers the most forgiving outcome.

2. Does the patient genuinely value spectacle independence?

Motivation predicts satisfaction more reliably than refraction. Useful probes:

• "Which activities would you most like to do without glasses — reading, phone, driving at night?"
• "Have you ever worn multifocal contact lenses? How did you find them?" (Prior multifocal contact lens tolerance is one of the best informal predictors.)
• "If you still needed thin readers for very small print, would you consider the surgery a success?"

A patient who wants spectacle independence at any cost is a stronger multifocal candidate than one who wants perfect vision. Perfectionists belong in monofocals with mini-monovision, or in an EDOF design with a gentler dysphotopsia profile.

3. Can the refractive target be hit reliably?

Multifocal optics magnify biometry error. A 0.50 D surprise that a monofocal patient shrugs off can leave a premium-lens patient unhappy despite a technically perfect operation. Before committing:

• Use modern optical biometry and a fourth- or fifth-generation formula; re-measure when keratometry repeats differ.
• Manage ocular surface disease before final biometry — not after.
• Correct meaningful corneal astigmatism, whether with a toric IOL or a toric-multifocal, since residual cylinder above roughly 0.75 D erodes the multifocal advantage.
• Plan for capsular stability: a lens that rotates or tilts postoperatively undermines a diffractive optic. Hydrophobic acrylic platforms with high capsular adhesion — see our guide on why IOL material matters for long-term outcomes — reduce that risk.

4. Can the patient tolerate the neuroadaptation curve — and can your chair time absorb it?

Honest counselling about halos, glare, and a three-to-six-month adaptation window converts potential complaints into expected physiology. Practices that document this conversation, ideally with a written pre-op information sheet, report fewer premium-lens escalations. If the patient's temperament or your follow-up capacity cannot support the adaptation journey, choose the lens that performs well on day one: the monofocal.

The Middle Path: EDOF and Enhanced Monofocals

The binary framing of "monofocal versus multifocal" is increasingly outdated. Extended depth-of-focus lenses stretch a single focal point rather than splitting light into discrete foci, trading some near acuity for a dysphotopsia and contrast profile much closer to a monofocal. For borderline candidates — mild, stable comorbidity; moderate spectacle-independence motivation; night drivers — an EDOF or enhanced-monofocal platform often captures most of the lifestyle benefit with a fraction of the risk. It is a defensible default for the undecided middle, and it deserves a permanent seat in your counselling menu alongside conventional monofocal and multifocal options.

Monovision: The Underused Evidence-Based Alternative

Mini-monovision (typically −0.75 D to −1.25 D in the non-dominant eye) with aspheric monofocals achieves functional intermediate and partial near vision in a large share of patients, at standard-lens cost, with minimal dysphotopsia. The caveats are real — it demands accurate biometry, a cooperative dominant eye, and ideally a contact-lens trial in presbyopic-naïve patients — but for cost-sensitive settings and high-volume lists across India, Southeast Asia, and Africa, monofocal-based mini-monovision remains the most evidence-efficient route to reduced spectacle dependence. It also future-proofs the eye: no diffractive optic to explain at a future retinal referral.

Grading Comorbidity: A Simple Traffic-Light System

Surgeons often ask where exactly to draw the line on "mild" disease. A pragmatic traffic-light approach, adapted from premium-IOL selection protocols used in high-volume refractive-cataract practices, works well:

• Green (multifocal acceptable): no macular pathology on OCT; regular astigmatism ≤1.5 D treatable with toric optics; healthy tear film or mild dry eye that resolves with two weeks of treatment; early, controlled glaucoma suspects with full fields.
• Amber (EDOF or enhanced monofocal): trace drusen without fluid; well-controlled ocular hypertension; mild Fuchs' change with clear central cornea; post-LASIK corneas with good topographic quality; high myopes with stable peripheral retina.
• Red (monofocal only): any epiretinal membrane with foveal distortion, diabetic maculopathy or prior macular oedema, manifest glaucoma with field defect, irregular astigmatism, keratoconus, amblyopia, or prior corneal refractive surgery with multifocal ablations.

The amber zone is where most real-world patients live — and where the framework earns its keep. Documenting the traffic-light grade in the chart takes thirty seconds and becomes invaluable if dissatisfaction arises later.

A Counselling Script That Works

Lengthy consent lectures lose patients; vague reassurance loses trust. A tight three-part script covers what matters:

1. Mechanism in one sentence: "This lens splits light so you can see far and near at the same time — like having two focus points instead of one."
2. Trade-off in one sentence: "Around lights at night you may notice rings or halos; most patients stop noticing them within a few months, but a few do not."
3. Expectation in one sentence: "You will do most things without glasses, but very small print or long reading sessions may still be more comfortable with light readers."

Then stop talking and ask the patient to describe their typical day. The answer tells you more than any questionnaire score. A chartered accountant who reads spreadsheets for ten hours a day needs a different lens from a retired farmer who drives his grandchildren to school and watches cricket in the evening.

The Fellow-Eye Opportunity

Cataract surgery is sequential, which gives you a built-in feedback loop. Schedule the second eye only after reviewing the first at four to six weeks. If the first-eye multifocal patient is adapting well and the refractive result is on target, proceed symmetrically. If there are complaints — halos dominating night driving, a −0.75 D surprise — the second eye is your correction instrument: mix an EDOF with the multifocal, adjust the target with mini-monovision, or switch platforms entirely. Surgeons who treat bilateral surgery as two independent decisions consistently report higher bilateral satisfaction than those who lock in a bilateral plan at the first consultation.

Practice Economics and the Premium Channel

For ambulatory surgery centres and high-volume hospitals, the decision framework has a commercial shadow:

• Counselling cost: A multifocal conversion costs 10–20 additional staff minutes per patient. Build that into premium-lens pricing.
• Enhancement policy: Decide in advance who pays for refractive touch-ups and lens exchanges, and put it in writing.
• Inventory discipline: Stocking a full premium range ties up capital. Many centres standardise on one monofocal platform, one toric, and one trifocal or EDOF, with consignment arrangements for outliers. Preloaded IOL systems reduce handling variability and turnaround time regardless of which optic you select.

A disciplined framework — one that routes only genuinely suitable eyes to premium optics — protects both your refractive reputation and your refund rate.

Practical Takeaways for the Operating List

1. Screen the macula with OCT before offering any light-splitting lens.
2. Treat the ocular surface before final biometry; repeat Ks that disagree.
3. Use the four-question framework as a documented checklist in the chart.
4. Default borderline candidates to EDOF or enhanced monofocal rather than a full multifocal.
5. Offer mini-monovision explicitly; it is evidence-based, not a compromise.
6. Put the dysphotopsia conversation and enhancement policy in writing, preoperatively.
7. Standardise your IOL formulary; consistency in platform behaviour beats catalogue breadth.

Frequently Asked Questions

What is the main difference between monofocal and multifocal IOLs?

A monofocal IOL focuses light at a single distance, usually far, with readers needed for near tasks. A multifocal IOL splits incoming light into two or more focal points, providing distance and near vision simultaneously and reducing spectacle dependence at the cost of some contrast and possible halos.

Who should not receive a multifocal IOL?

Patients with macular disease, glaucoma with field loss, irregular corneal astigmatism, significant dry eye, amblyopia, or unrealistic perfectionist expectations are poor multifocal candidates. These eyes cannot spare the contrast a light-splitting optic sacrifices, and dissatisfaction rates rise sharply in their presence.

Do patients adapt to halos after multifocal IOL implantation?

Most do. Neuroadaptation typically reduces halo and glare awareness over three to six months. Documented preoperative counselling about this adaptation window significantly lowers complaint rates; a small minority of patients remain symptomatic and may require lens exchange.

Is mini-monovision a good alternative to multifocal IOLs?

Yes, for selected patients. Targeting mild myopia (around −1.0 D) in the non-dominant eye with monofocal lenses delivers useful intermediate and partial near vision with minimal dysphotopsia and standard-lens cost, provided biometry is accurate and the patient tolerates anisometropia.

Which is better for night driving: monofocal or multifocal IOL?

Monofocal IOLs generally perform better for night driving because they preserve full contrast sensitivity and produce fewer halos around headlights. Patients who drive frequently at night, including professional drivers, should usually be counselled toward monofocal or EDOF optics rather than diffractive multifocals.

---

Ready to standardise your IOL formulary? Explore Oculentis Medical's CE Marked, CDSCO-licensed range of monofocal, multifocal, toric, and EDOF intraocular lenses, manufactured in Mumbai under ISO 13485. Request a product sample or contact our clinical team to discuss platform selection for your practice. Before use, consult the Instructions for Use (IFU) supplied with each product for complete indications, contraindications, warnings, and precautions. Product availability and regulatory status vary by country.

---

This article is for educational purposes and is intended for healthcare professionals. It does not constitute medical advice and does not replace the Instructions for Use supplied with each product. Clinical decisions should be based on the surgeon's professional judgement, the individual patient's condition, and the current product IFU. Regulatory status varies by country; please contact Oculentis Medical for information specific to your market.